PROCTER & GAMBLE HEALTH | ASTRAZENECA PHARMA | PROCTER & GAMBLE HEALTH/ ASTRAZENECA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.5 | 95.5 | 36.1% | View Chart |
P/BV | x | 10.5 | 22.7 | 46.3% | View Chart |
Dividend Yield | % | 2.0 | 0.3 | 671.2% |
PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ASTRAZENECA PHARMA Mar-23 |
PROCTER & GAMBLE HEALTH/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 3,620 | 148.2% | |
Low | Rs | 3,883 | 2,438 | 159.3% | |
Sales per share (Unadj.) | Rs | 740.7 | 401.2 | 184.6% | |
Earnings per share (Unadj.) | Rs | 138.2 | 39.7 | 348.1% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 46.2 | 335.7% | |
Dividends per share (Unadj.) | Rs | 95.00 | 16.00 | 593.8% | |
Avg Dividend yield | % | 2.1 | 0.5 | 388.9% | |
Book value per share (Unadj.) | Rs | 447.6 | 234.4 | 190.9% | |
Shares outstanding (eoy) | m | 16.60 | 25.00 | 66.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 7.5 | 82.7% | |
Avg P/E ratio | x | 33.5 | 76.3 | 43.9% | |
P/CF ratio (eoy) | x | 29.8 | 65.5 | 45.5% | |
Price / Book Value ratio | x | 10.3 | 12.9 | 80.0% | |
Dividend payout | % | 68.7 | 40.3 | 170.6% | |
Avg Mkt Cap | Rs m | 76,761 | 75,718 | 101.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 2,591 | 79.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 10,030 | 122.6% | |
Other income | Rs m | 184 | 261 | 70.5% | |
Total revenues | Rs m | 12,480 | 10,291 | 121.3% | |
Gross profit | Rs m | 3,247 | 1,249 | 260.0% | |
Depreciation | Rs m | 281 | 163 | 172.8% | |
Interest | Rs m | 8 | 6 | 122.2% | |
Profit before tax | Rs m | 3,142 | 1,341 | 234.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 348 | 243.4% | |
Profit after tax | Rs m | 2,295 | 993 | 231.1% | |
Gross profit margin | % | 26.4 | 12.5 | 212.1% | |
Effective tax rate | % | 27.0 | 26.0 | 103.9% | |
Net profit margin | % | 18.7 | 9.9 | 188.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 9,359 | 125.1% | |
Current liabilities | Rs m | 6,791 | 4,844 | 140.2% | |
Net working cap to sales | % | 40.0 | 45.0 | 88.9% | |
Current ratio | x | 1.7 | 1.9 | 89.3% | |
Inventory Days | Days | 263 | 49 | 531.1% | |
Debtors Days | Days | 343 | 39 | 877.8% | |
Net fixed assets | Rs m | 10,617 | 2,061 | 515.0% | |
Share capital | Rs m | 166 | 50 | 332.0% | |
"Free" reserves | Rs m | 7,265 | 5,811 | 125.0% | |
Net worth | Rs m | 7,431 | 5,861 | 126.8% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 11,421 | 195.5% | |
Interest coverage | x | 409.1 | 213.9 | 191.3% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.9 | 62.7% | |
Return on assets | % | 10.3 | 8.7 | 117.9% | |
Return on equity | % | 30.9 | 16.9 | 182.3% | |
Return on capital | % | 42.4 | 23.0 | 184.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 37.4 | 34.9% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | 3,747 | 42.8% | |
Fx inflow | Rs m | 1,465 | 612 | 239.4% | |
Fx outflow | Rs m | 1,605 | 3,747 | 42.8% | |
Net fx | Rs m | -140 | -3,135 | 4.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 583 | 404.9% | |
From Investments | Rs m | -215 | 181 | -118.7% | |
From Financial Activity | Rs m | -985 | -245 | 402.2% | |
Net Cashflow | Rs m | 1,160 | 519 | 223.5% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 51.8 | 75.0 | 69.1% | |
Indian inst/Mut Fund | % | 20.3 | 5.4 | 373.8% | |
FIIs | % | 7.6 | 2.7 | 285.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 25.0 | 192.7% | |
Shareholders | 56,730 | 29,032 | 195.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | ASTRAZENECA PHARMA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.55% | 0.01% | 1.18% |
1-Month | -7.47% | -3.61% | -0.75% |
1-Year | -3.02% | 59.20% | 61.82% |
3-Year CAGR | -9.12% | 20.50% | 18.16% |
5-Year CAGR | 5.75% | 22.18% | 19.79% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the ASTRAZENECA PHARMA share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of ASTRAZENECA PHARMA the stake stands at 75.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of ASTRAZENECA PHARMA.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
ASTRAZENECA PHARMA paid Rs 16.0, and its dividend payout ratio stood at 40.3%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of ASTRAZENECA PHARMA.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.